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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
1. To assess the effectiveness, safety and appropriate dose regimen of ERT in people with MPS IV A.
2. To determine whether evidence from NRSIs (which potentially offers longer follow-ups) can contribute to the ERT efficacy
evidence-base, and to determine the potential need for additional RCT evidence.
3. To consolidate recommendations for the design of future clinical trials.
B A C K G R O U N D
Please refer to the glossary of terms (Appendix 1).
Description of the condition
Mucopolysacharidoses (MPS) are a group of lysosomal storage dis-
orders (LSDs) which are characterized by the accumulation of ex-
tracellular macromolecules named glycosaminoglycans (GAGs).
These macromolecules have structural significance in the building
of connective tissue and cartilage, and are also important agents
for the regulation of diverse biochemical cascades, such as coagula-
tion, immune response andpathogen recognition and removal (the
complement system), inter-cellular communications and wound
healing (Linhardt 2004). Given their complex structure, several
enzymes are needed for the complete lysosomal breakdown of
these macromolecules. Deficiency in any of the enzymes leads to
the accumulation of GAGs in high concentrations, mainly inside
chondrocytes and in the extracellular matrix, leading to inflam-
mation and apoptosis (cell death). Morquio syndrome is one of
the seven known phenotypes of MPS, classified into two types
based on the enzymatic deficiency: type IVA galacosamine 6 sulfa-
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tase (GALNS) deficiency (Morrone 2014) (OMIM #253000) and
type IV B beta galactosidase deficiency (Bonafe 2015) (OMIM
#253010), both resulting in a defective catabolic process of ker-
atan sulfate (KS). The reduced capacity to fully degrade KS re-
sults in its accumulationwithin the skeletal system, visceral organs,
heart valves and the eyes (Yasuda 2013). This review will focus on
MPS IV A. Prominent features of MPS IV A are skeletal dyspla-
sia (short stature, pectus carinatum, kyphosis, joint abnormalities,
odontoid hypoplasia) (Di 2012), hepatomegaly (enlarged liver)
(Montano 2007), anomalies of the teeth (James 2012), corneal
clouding (Montano 2007), hearing difficulties (Harmatz 2013)
and heart valve defects (Hendriksz 2013a).
Description of the intervention
The concept of enzyme replacement therapy (ERT), an intra-
venous administration of recombinant enzymes, was initially de-
veloped as a treatment for Gaucher disease, and is now an estab-
lished treatment modality for many LSDs, including MPS IV A
(Lachmann 2011). In 2014, a recombinant human GALNS en-
zyme (rhGALNS, elosulfase alfa, BMN110, Vimizim®, BioMarin
Pharmaceutical Inc., USA) was approved by the US Food and
Drug Administration for use. The use of ERT inMPS IV is gener-
ally considered safe, with few hypersensitivity reactions, and rare
cases of anaphylaxis (Hendriksz 2014). Known adverse events are
vomiting, pyrexia and headaches (Hendriksz 2016; Jones 2015).
How the intervention might work
In MPS IV A, similar to other LSDs such as Gaucher disease, a
deficient or malfunctioning enzyme leads to the accumulation of
its substrate, KS. ERT is the process of systemic administration of
a synthetically-produced enzyme. The systemically administered
enzyme enters the lysosomal compartment of different cells via
mannose-6-phosphate receptors on the plasmamembrane (Mistry
1996), a specific protein uptake mechanism.
Why it is important to do this review
As in other ultra-rare orphan disorders, the body of evidence for
treatment efficacy in MPS IV is sparse. This can be explained by
the low number of people with the disorder and their heterogene-
ity; the course of the disease (a chronic disorder with diverse man-
ifestations); and the differences between study protocols. All of
these inherent issues limit the ability to perform randomised con-
trolled trials (RCTs). Rare disease populations are also spread over
wide geographical areas of the world and this increases the num-
ber of clinical trial sites with small numbers of participants as an
additional confounder. It is worthwhile mentioning that most of
the evidence regarding treatment efficacy in fact comes from non-
randomised studies (NRSIs), e.g. patient registries. For example, a
PubMed search of MPS IV A and ’randomised controlled trial’ as
MeSH terms yields six results, while when combined with ’cohort
studies’ it results in 40 studies. Hitherto, the production of a valu-
able evidence-based systematic review on treatment efficacy using
’classical’ Cochrane methodology is likely to be beset with many
limitations, as discussed by the authors undertaking this review in
a further Cochrane Review on Gaucher disease (Shemesh 2015).
Here, we plan to perform a Cochrane Review incorporating data
from both RCTs and NRSIs, to assess treatment efficacy for MPS
IV A, and to conclude whether such an approach will benefit a
systematic review of an ultra-rare disorder.
O B J E C T I V E S
1. To assess the effectiveness, safety and appropriate dose
regimen of ERT in people with MPS IV A.
2. To determine whether evidence from NRSIs (which
potentially offers longer follow-ups) can contribute to the ERT
efficacy evidence-base, and to determine the potential need for
additional RCT evidence.
3. To consolidate recommendations for the design of future
clinical trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs (including open-label trials, cross-over trials and cluster
randomised trials).
Since long-term effects are less likely to be evaluated in RCTs,
because of the limited body of evidence emerging from RCTs on
efficacy and safety in rare diseases, and in accordance to EPOC
recommendations (EPOC2017a), the following study designswill
also be assessed (regardless of length of follow-up):
1. NRSIs;
2. prospective cohort studies;
3. controlled before-after studies.
Due to the lack of formal guidelines regarding the inclusion of
NRSIs in Cochrane Reviews, two authors (ES, LD) will individ-
ually assess these studies and determine their eligibility for inclu-
sion. Any uncertainties regarding eligibility for inclusion will be
discussed by all authors.
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Despite the beneficial potential these studies may hold for a sys-
tematic review, NRSIs are more likely to have intrinsic confound-
ing factors, and thus are prone to bias. We will therefore assess
included NRSIs for the presence of confounders:
1. age;
2. height;
3. walking ability (stratified to less than 30 m; 30 to 200 m;
further than 200 m); and
4. previous surgical procedures.
Following the guidance provided in chapter 13 of the Cochrane
Handbook for Systematic reviews of interventions, we will also con-
sider whether participant selection was restricted or balanced in
relation to these confounders and whether matching or adjust-
ments were conducted in statistical analyses (Reeves 2011).
Types of participants
Individuals with MPS IV A of any age and of any disease severity.
Types of interventions
ERT with elosulfase alfa compared to placebo, or a comparison of
different doses (e.g. 1 to 4 mg/kg).
Types of outcome measures
Primary outcomes
1. Endurance (measures of walking distance)
i) six-minute walk test (6MWT)
ii) three-minute stair climb test (3MSCT)
2. Safety and tolerability (reported side effects, development
of antibodies to the enzyme)
3. Pulmonary function measures (absolute values)
i) forced vital capacity (FVC) (litres)
ii) maximum voluntary ventilation (MVV) (L/min)
iii) forced expiratory volume in 1 second (FEV1) (L)
Secondary outcomes
1. Weight (kg)
2. Urinary KS levels (µ mg/mg normalized for creatinine)
3. Quality of life (QoL) scores (measured by, e.g. the Health
Assessment Questionnaire, and the EurQol 5D scales)
4. Pain (e.g. using the visual analogue scale (VAS))
We will prefer to analyse the continuous outcomes (endurance,
pulmonary functions, weight, urinary KS levels, QoL scores and
pain) as change from baseline. If data will not be sufficient, we
will use post-treatment scores.
All outcomes, irrespective of original study design, will be assessed
following the division to four time points. This division follows
the length of the published studies:
1. up to six months;
2. six months and up to 12 months;
3. 12 months and up to 24 months;
4. 24 months and above.
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
We will identify relevant studies from the Cystic Fibrosis and Ge-
netic Group’s Inborn Errors of Metabolism Trials Register using
the term: mucopolysaccharidosis.
The Inborn Errors of Metabolism Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of the Cochrane
Library), weekly searches ofMEDLINE and the prospective hand-
searching of one journal - Journal of Inherited Metabolic Disease.
Unpublished work is identified by searching through the abstract
books of the Society for the Study of Inborn Errors of Metabolism
conference and the SHS Inborn Error Review Series. For full de-
tails of all searching activities for the register, please see the relevant
section of the Cochrane Cystic Fibrosis and Genetic Disorders
Group’s website.
In addition to the above, we will conduct a search of the following
databases and trial registers:·
• PubMed (www.ncbi.nlm.nih.gov/sites/entrez; 1946 to
present);·
• ClinicalTrials.gov (www.ClinicalTrials.gov);·
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) Search Portal (apps.who.int/
trialsearch/).
See Appendix 2 for the full search strategies.
Searching other resources
Reference lists
The reference lists of all included articles and relevant systematic
reviews will be reviewed to identify any additional studies.
Handsearching and experts
We will search through abstract books of the Lysosomal Disease
Network (LDN) conference (last five years), and contact experts
in the field in attempt to retrieve any further relevant data.
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Data collection and analysis
Selection of studies
Regardless of study design, two authors (ES, LD) will indepen-
dently assess and discuss the papers identified by the initial searches
in order to decide whether theymeet the inclusion criteria. Should
any disagreements on study eligibility arise, we will reach a con-
sensus by consultation with the remaining three authors (CJH,
CH, AK).
Data extraction and management
Two authors (ES, LD) will independently extract the data (with
input from a third author as necessary (AK)) using standard data
extraction forms which will include information about the follow-
ing:
1. methods of the study (type of study, number of participants
and dropouts);
2. characteristics of the study population;
3. type of intervention;
4. data for assessing the risk of bias:
i) for RCTs: methods of randomisation, whether
blinding was applied (and who was blinded), type of sequence
generation used, and type of allocation concealment used);
ii) for NRSIs: presence of potential confounders
influencing assignment to interventions (1. age; 2. height; 3.
walking ability (stratified to less than 30 m, 30 m to 200 m,
further than 200 m); and 4. previous surgical procedures), loss to
follow-up details, whether the selection of participants was
biased, whether a deviation from intended interventions had
occurred (performance bias);
5. outcomes and results (means, standard deviations (SDs) or
standard errors (SEs)). In the case of non-randomised cohort
studies, we will prefer to extract treatment effects for differences
adjusted for baseline differences between groups in potential
confounding factors.
If additional data are needed, we will contact study investigators
or calculate the missing values (based on available data) or impute
these (if possible).
Given that combining randomised and non-randomised evidence
is not recommended due to fundamental differences in study de-
sign, we plan to analyse these different types of studies separately.
Assessment of risk of bias in included studies
We will assess the risks of bias using ROB 2.0 for RCTs, and using
ROBINS-I for NRSIs.
RCTs
We will assess the included RCTs using the Cochrane risk of
bias assessment tool, focusing on the following domains (Higgins
2011a).
Assessment of sequence generation
1. Low: if allocation sequence is suitable to prevent selection
bias (i.e. computer-generated lists, coin tossing, shuffling cards
or envelopes, random number table, etc.).
2. High: if allocation sequence could be related to prognosis
and thus introduce selection bias (i.e. date of admission, clinical
judgement, participant preference, results of laboratory tests,
availability of intervention, date of birth, etc.).
3. Unclear: if there is insufficient information regarding the
sequence generation.
Assessment of allocation concealment
1. Low: if investigators were shielded from predicting the
assignment of participants into the intervention groups (i.e.
central randomisation was done by telephone or by a pharmacy,
identical and sequentially numbered drug containers or
sequentially numbered, sealed and opaque envelopes).
2. High: if investigators were not shielded from predicting the
assignment of participants into the intervention groups (i.e. non-
opaque envelopes, open allocation schedule, etc.).
3. Unclear: if the method of concealment is not described.
Assessment of blinding
1. Low: if no blinding was done, but outcome was not likely
to be influenced by the lack of blinding; or if blinding was
ensured and was unlikely to be broken.
2. High: if no blinding was done, and outcome was likely to
be affected by the lack of blinding; or blinding was attempted
but could have been broken.
3. Unclear: if the method of blinding is not described.
Incomplete data
Wewill consider whether it was stated howmany participants were
lost to follow-up, and reasons for this given; also if loss to follow-
up did occur, whether or not an intention-to-treat (ITT) analysis
was performed. According to these criteria, we will define three
levels of risk of bias as follows.
1. Low risk: if the number or reasons (or both) for loss to
follow-up were mentioned, and if an ITT analysis was carried
out.
2. High risk: if number or reasons (or both) for loss to follow
up were not mentioned, or ITT analysis was not carried (or
both).
3. Unclear risk: if the original study did not specify the way
loss to follow-up was handled.
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Selective outcome reporting
We aim to assess the consistency of outcomes which the original
investigators planned to report during the study, to those actually
reported within the published paper, by comparing the study pro-
tocols and registries with the information in the final publication.
If the protocols are not available, we will compare the methods
section of the publication to the published results, in order to as-
sess whether all outcomes were indeed reported and to determine
if selective outcome reporting occurred.
Other sources of bias
We will review relevant studies for other potential sources of bias,
such as: deviation from study protocol; early cessation of the study;
selective reporting of subgroups; or a bias due to poor delivery of
the interventions.
NRSIs
We will assess the risk of bias in NRSIs using the ROBINS-I do-
mains as below (Sterne 2016). The effect of assignment to inter-
vention will be estimated. We will define five levels of risk for each
domain.
1. Low risk of bias: the study is comparable to a well
performed RCT, with regard to the specific domain being
assessed.
2. Moderate risk of bias: the study has a solid methodology for
a NRSI with regard to the specific domain being assessed, but
cannot be considered comparable to a well-performed RCT.
3. Serious risk of bias: the study has important methodological
problems with regard to the specific domain being assessed.
4. Critical risk of bias: the study has a severe methodological
issue in the specific domain, which precludes the drawing of any
useful evidence on the effects of intervention.
5. No information available to base a judgement about risk of
bias for a specific domain.
Bias due to confounding
We will review whether one or more prognostic variables (as de-
fined above in Data collection and analysis) also predicts the in-
tervention received at baseline.
Bias in selection of participants
When exclusion of some eligible participants, or the initial follow-
up time of some participants, or some outcome events is related
to both intervention and outcome, there will be an association
between interventions and outcome even if the effects of the inter-
ventions are identical This form of selection bias is distinct from
confounding - a specific example is bias due to the inclusion of
prevalent users, rather than new users, of an intervention.
Bias in classification of interventions
We will assess bias introduced by either differential or non-differ-
ential misclassification of intervention status.
Bias due to deviations from intended interventions
We will consider systematic differences between experimental in-
tervention and comparator groups in the care provided, which
represent a deviation from the intended intervention(s).
Bias due to missing data
We will review whether later follow-up is missing for individuals
initially included and followed (such as differential loss to follow-
up that is affected by prognostic factors).
Bias in measurement of outcomes
We will review bias introduced by either differential or non-dif-
ferential errors in measurement of outcome data.
Bias in selection of the reported results
Selective reporting of results, depending on the findings.
We will estimate an overall risk of bias utilizing the assessment
of each of these domains. The overall risk of bias for NRSIs will
follow the same division to five levels of bias.
1. Low risk of bias: the study is comparable to a well-
performed RCT.
2. Moderate risk of bias: the study provides sound evidence for
a NRSI, but cannot be considered comparable to a well-
performed RCT.
3. Serious risk of bias: the study has some methodological
issues.
4. Critical risk of bias: the study suffers from too many
methodological issues, thus not providing any useful evidence
and should not be included in the synthesis.
5. No information on which to base a judgement about risk of
bias.
Measures of treatment effect
We will analyse adverse events as dichotomous data by calculating
the odds ratio (OR) and 95% confidence intervals (CIs). For all
other outcomes, given that we consider it likely that the original
study reports will have utilised various scales and measurements
to assess the relevant continuous outcomes, we plan to analyse the
data by calculating the standardized mean difference (SMD) and
the corresponding 95%CIs. If the studies do not report post-inter-
vention results adjusted for baseline, but instead present absolute
post-treatment data without baseline values (so it is not possible
to calculate change data), we will consider using absolute post-
treatment data instead.
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Wewill synthesise andpresent all componentswithin one outcome
domain together.
Unit of analysis issues
For RCTs, when combining results from cross-over trials in ameta-
analysis, we plan to use the methods recommended by Elbourne
(Elbourne 2002). For studies with multiple treatment groups we
will include subgroups that are considered relevant to the analysis.
When appropriate, we will combine groups to create a single pair-
wise comparison. If this is not possible, we will select the most
appropriate pair of interventions and exclude the others (Higgins
2011b). For NRSIs, studies may measure data over multiple time
points; given these data will have a correlated structure, we plan
to analyse the data based on the pre-defined time periods (as with
RCT data), adjusted for confounders (see Data extraction and
management).
Dealing with missing data
If some of the numerical data are missing from the identified
studies (e.g. SDs), we will contact the original investigators and
request these data. If we are unable to retrieve these data, we will
attempt to calculate missing data by utilising the available data
(e.g. when a SD is not reported, it may be calculated based on
given CIs, the mean, and the number of participants). If this is not
possible, we will attempt to impute SDs based on similar studies
(i.e. interventions, time points, population) (Higgins 2011b). For
NRSIs, if information regarding confounders is missing, we will
contact the original investigators for clarification. If we are unable
to retrieve such information or estimate it based on similar cohorts,
we will adapt the risk of bias for such studies accordingly.
Assessment of heterogeneity
In order to assess heterogeneity between studies, we will assess the
forest plots visually, and will use the I² statistic (Higgins 2003) and
the Chi² test and its corresponding P value, as stated in chapter
9 of the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011). We will consider values of 0% to 50% as not im-
portant, 50% to 75% as moderate, and 75% to 100% as consid-
erable heterogeneity.
Assessment of reporting biases
Where sufficient data are available (10 or more studies per out-
come assessed), we will assess potential publication bias by con-
structing and assessing the symmetry of a funnel plot. If we detect
asymmetry, we will explore causes other than publication bias.
Data synthesis
Given that combining randomised and non-randomised evidence
is not recommended due to the fundamental differences in study
design,we plan to analyse these different types of studies separately.
RCTs
For RCTs, we plan to use a fixed-effectmodel to synthesize the data
(inverse-variancemethod). If the included trials are not sufficiently
homogeneous to be combined in a meta-analysis, we will display
the results of included studies in a forest plot, suppressing the
pooled estimate.
NRSIs
Because of the likelihood presence of heterogeneity betweenNRSI
we plan to use a random-effects model to synthesize the data,
due to anticipated heterogeneity between cohort studies (emerging
from different adjustment for confounders, covariates in adjusted
models etc.).
If the included studies are not sufficiently homogeneous to be
combined in a meta-analysis (I² > 60%), we will display the results
of included studies in a forest plot, suppressing the pooled estimate.
Subgroup analysis and investigation of heterogeneity
We aim to undertake a subgroup analysis by age (under and over
14 years of age). We intend to sub-divide our analysis using the
age of 14 years as a cut-off since final growth of people with MPS
IV is achieved by that age. Therefore, it would be of interest to
analyse data from the period in which ERT is likely to have an
effect on growth.
Sensitivity analysis
For both sets of analyses (RCTs and NRSIs), if there are at least
10 comparable studies, we will perform a sensitivity analysis by
excluding those trials with an overall high risk of bias.
Summary of findings tables
The summary of findings tables will provide information regard-
ing participant population, the interventions compared, the main
results and the quality of these findings (based on risk of bias,
inconsistency, indirectness, imprecision and publication bias). We
will report the following main outcome measures.
1. Endurance
2. Pulmonary function measures
3. Anthropometric measures
4. Safety and tolerability
5. QoL score
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Data from NRSIs will be presented separately; the quality of these
studieswill be considered ’low’ to beginwith, andmay be upgraded
if the following criteria are met:
1. dose response;
2. large size of the effect;
3. confounding reduces or increases the demonstrated effect.
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A P P E N D I C E S
Appendix 1. Glossary of terms
Term Definition
Macromolecule A molecule composed of a very large number of atoms, such as proteins
Glycosaminoglycans Macromolecules made up from protein and sugar molecules.
Catabolic process A metabolic process that breaks down molecules into small units, which are then usable in the body systems
Pyrexia A raise in body’s temperature, also called fever by many people
Dysplasia Abnormalities of usually the bones which may cause very abnormal looking features depending on which
bones are affected
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(Continued)
Pectus carinatum A developmental anomaly characterized by abnormal anterior protrusion of the sternum (a bone in the chest)
and adjacent costal cartilage; Also called pigeon chest
Kyphosis Deformities of the spine characterized by an exaggerated convexity of the vertebral column which cause the
spine to look more curved than normal
Odontoid hypoplasia Improper development, or a complete absence, of a bony projection from the second cervical spinal bone.
This process is like a peg; It helps to hold the top two parts of the spine together and protect the spinal cord
from being squashed or damaged by allowing too much movement
Appendix 2. Search strategies
Database/ Resource Strategy
PubMed (1946-present) (Mucopolysaccharidosis iv[tw] ORMucopolysaccharidosis iva[tw]
OR Mucopolysaccharidosis ivb[tw] OR mps iv*[tw] OR
*Morquio*[tw] OR “Mucopolysaccharidosis IV”[Mesh]) AND
(enzyme replacement therapy[MeSH] OR (enzyme* AND re-
place*) OR elosulfase[tw] OR vimizim[tw])
ClinicalTrials.gov CONDITION/DISEASE:Mucopolysaccharidosis iv ORMPS iv
OR Morquio
OTHER TERMS: enzyme OR elosulfase OR vimizim
WHO International Clinical Trials Registry Platform (ICTRP) Mucopolysaccharidosis iv* OR MPS iv* OR Morquio
C O N T R I B U T I O N S O F A U T H O R S
ES, CH and CJH formulated the research questions. Outcomes and subgroup analyses were discussed by all authors. Writing of the
first protocol draft was done by ES. The final version of the protocol was written by all authors. Data collection, analyses and bias
assessments will be done by ES and LD, assisted by AK as required. Data interpretation will be done by all authors: CH and CJH will
provide clinical perspectives, LD and ES will provide methodological insight and AK will provide statistical input. ES is regarded as
the ’guarantor’ of this review.
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